The American Diabetes Association’s 84th Scientific Sessions will focus on new endpoints for diabetes management tools and best practices for optimization. Emerging research on GLP-1 receptor agonists shows benefits beyond obesity, such as in kidney and cardiovascular diseases. Trials on drugs like tirzepatide and once-weekly semaglutide will be highlighted. Sessions will cover debates on prioritizing anti-obesity medications, potential downsides of GLP-1 agonists, and new uses for old drugs like fenofibrate in diabetic retinopathy. Major trials will also explore novel treatments for type 1 and type 2 diabetes, including inhaled insulin and consensus guidance for high-risk individuals. The event promises a wealth of valuable information and insights for attendees.
Source link
ADA Scientific Sessions 2024 Go Beyond Glucose and Obesity
